NL194300C - Farmaceutisch preparaat, dat een polyprenol als werkzaam bestanddeel bevat, alsmede voor toepassing daarin geschikte polyprenolen. - Google Patents

Farmaceutisch preparaat, dat een polyprenol als werkzaam bestanddeel bevat, alsmede voor toepassing daarin geschikte polyprenolen. Download PDF

Info

Publication number: NL194300C
Authority: NL; Netherlands
Prior art keywords: compound; polyprenols; polyprenol; formula; preparation
Prior art date: 1982-05-28

Application number

NL8301892A

Other languages

English (en)

Dutch (nl)

Other versions

NL8301892A (nl

NL194300B (nl

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-05-28

Filing date

1983-05-27

Publication date

2001-12-04

1982-05-28 Priority claimed from JP57089806A external-priority patent/JPS58206517A/ja

1982-06-22 Priority claimed from JP10620382A external-priority patent/JPS58225014A/ja

1982-10-21 Priority claimed from JP18364382A external-priority patent/JPS5973533A/ja

1982-10-21 Priority claimed from JP18364282A external-priority patent/JPS5973513A/ja

1983-05-27 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1983-12-16 Publication of NL8301892A publication Critical patent/NL8301892A/nl

2000-12-05 Priority to NL9900009A priority Critical patent/NL9900009A/nl

2001-08-01 Publication of NL194300B publication Critical patent/NL194300B/xx

2001-12-04 Application granted granted Critical

2001-12-04 Publication of NL194300C publication Critical patent/NL194300C/nl

Links

229930186185 Polyprenol Natural products 0.000 title claims description 38
229920001731 Polyprenol Polymers 0.000 title claims description 38
150000003096 polyprenols Chemical class 0.000 title claims description 38
BDMCAOBQLHJGBE-UHFFFAOYSA-N C60-polyprenol Natural products CC(=CCCC(=CCCC(=CCCC(=CCCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CCC(=C/CO)C)C)C)C)C)C)C)C)C)C)C)C BDMCAOBQLHJGBE-UHFFFAOYSA-N 0.000 title claims description 21
239000008194 pharmaceutical composition Substances 0.000 title claims description 9
239000004480 active ingredient Substances 0.000 title claims description 5
238000002360 preparation method Methods 0.000 claims description 32
RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims description 24
241001465754 Metazoa Species 0.000 claims description 21
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 14
230000000069 prophylactic effect Effects 0.000 claims description 10
229920006395 saturated elastomer Polymers 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 7
208000035473 Communicable disease Diseases 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 6
208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
244000144977 poultry Species 0.000 claims description 2
238000009472 formulation Methods 0.000 claims 1
238000002347 injection Methods 0.000 claims 1
239000007924 injection Substances 0.000 claims 1
244000144972 livestock Species 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 64
238000012360 testing method Methods 0.000 description 23
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
-1 for example Substances 0.000 description 10
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000000047 product Substances 0.000 description 9
239000003638 chemical reducing agent Substances 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
206010057249 Phagocytosis Diseases 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011734 sodium Substances 0.000 description 5
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 4
206010035664 Pneumonia Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000012230 colorless oil Substances 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 4
238000000921 elemental analysis Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000012280 lithium aluminium hydride Substances 0.000 description 4
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000000725 suspension Substances 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
238000000862 absorption spectrum Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
230000008782 phagocytosis Effects 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
RORDEOUGMCQERP-CMVHWAPMSA-N (2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-ol Chemical class CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO RORDEOUGMCQERP-CMVHWAPMSA-N 0.000 description 2
AJAKLDUGVSKVDG-UHFFFAOYSA-N 3,7,11,15-tetramethylhexadecan-1-ol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CCO AJAKLDUGVSKVDG-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical group CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
241000606790 Haemophilus Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000002921 anti-spasmodic effect Effects 0.000 description 2
239000003699 antiulcer agent Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000036737 immune function Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
239000000932 sedative agent Substances 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
238000001612 separation test Methods 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
RORDEOUGMCQERP-UHFFFAOYSA-N (2Z,6Z,10Z,14Z,18Z,22Z,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-tetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-ol Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO RORDEOUGMCQERP-UHFFFAOYSA-N 0.000 description 1
239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
OJISWRZIEWCUBN-QIRCYJPOSA-N (E,E,E)-geranylgeraniol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO OJISWRZIEWCUBN-QIRCYJPOSA-N 0.000 description 1
QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
239000005792 Geraniol Substances 0.000 description 1
GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000006758 Marek Disease Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000606860 Pasteurella Species 0.000 description 1
BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
241000949477 Toona ciliata Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000003212 astringent agent Substances 0.000 description 1
JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
235000000484 citronellol Nutrition 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
238000005187 foaming Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229940113087 geraniol Drugs 0.000 description 1
XWRJRXQNOHXIOX-UHFFFAOYSA-N geranylgeraniol Natural products CC(C)=CCCC(C)=CCOCC=C(C)CCC=C(C)C XWRJRXQNOHXIOX-UHFFFAOYSA-N 0.000 description 1
OJISWRZIEWCUBN-UHFFFAOYSA-N geranylnerol Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO OJISWRZIEWCUBN-UHFFFAOYSA-N 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
125000002560 nitrile group Chemical group 0.000 description 1
BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
229940045860 white wax Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/15—Unsaturated ethers containing only non-aromatic carbon-to-carbon double bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/203—Unsaturated compounds containing keto groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/08—Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
- C07C51/38—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by decarboxylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
- C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12C11/00—Fermentation processes for beer
- C12C11/02—Pitching yeast

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Food Science & Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8301892A 1982-05-28 1983-05-27 Farmaceutisch preparaat, dat een polyprenol als werkzaam bestanddeel bevat, alsmede voor toepassing daarin geschikte polyprenolen. NL194300C (nl)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
NL9900009A NL9900009A (nl)	1982-05-28	2000-12-05	Beta, gamma-dihydropolyprenylalcoholderivaten en farmaceutisch preparaat, dat een polyprenylverbinding bevat.

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
JP57089806A JPS58206517A (ja)	1982-05-28	1982-05-28	免疫機能不全による疾患の予防・治療剤
JP8980682		1982-05-28
JP10620382		1982-06-22
JP10620382A JPS58225014A (ja)	1982-06-22	1982-06-22	免疫機能不全による疾患の予防・治療剤
JP18364382		1982-10-21
JP18364382A JPS5973533A (ja)	1982-10-21	1982-10-21	β，γ−ジヒドロポリプレニルアルコ−ル誘導体
JP18364282		1982-10-21
JP18364282A JPS5973513A (ja)	1982-10-21	1982-10-21	免疫機能不全による疾患の予防・治療剤

Publications (3)

Publication Number	Publication Date
NL8301892A NL8301892A (nl)	1983-12-16
NL194300B NL194300B (nl)	2001-08-01
NL194300C true NL194300C (nl)	2001-12-04

Family

ID=27467677

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8301892A NL194300C (nl)	1982-05-28	1983-05-27	Farmaceutisch preparaat, dat een polyprenol als werkzaam bestanddeel bevat, alsmede voor toepassing daarin geschikte polyprenolen.

Country Status (12)

Country	Link
US (3)	US4624966A (de)
AT (1)	AT389871B (de)
CA (1)	CA1310660C (de)
CH (1)	CH654823A5 (de)
DE (2)	DE3318989C2 (de)
DK (1)	DK171640B1 (de)
ES (3)	ES8406992A1 (de)
FR (5)	FR2527597B1 (de)
GB (7)	GB2122610B (de)
IT (1)	IT1164256B (de)
NL (1)	NL194300C (de)
SE (4)	SE461650B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2122610B (en) *	1982-05-28	1987-04-01	Eisai Co Ltd	A polyprenyl compound and a pharmaceutical composition containing a polyprenyl compound
JPS6112622A (ja) *	1984-06-29	1986-01-21	Kuraray Co Ltd	造血幹細胞の分化増殖促進剤
JPH0759504B2 (ja) *	1986-01-23	1995-06-28	エーザイ株式会社	ポリプレニルアルコ−ル含有注射剤
US5071879A (en) *	1989-04-28	1991-12-10	Lidak Pharmaceuticals	Systemic antiviral treatment
US5070107A (en) *	1989-04-28	1991-12-03	Lidak Pharmaceuticals	Systemic antiviral treatment
JP3166991B2 (ja) *	1992-08-17	2001-05-14	日清製粉株式会社	（ｓ）−２，３−ジヒドロポリプレノール化合物を有効成分とする癌増殖抑制および／または癌転移抑制剤
US5602184A (en) *	1993-03-03	1997-02-11	The United States Of America As Represented By Department Of Health And Human Services	Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
CA2156063C (en) *	1993-12-13	1999-06-29	David H. Katz	Sucrose ester c-20 to c-28 alcohol formulations
TW338042B (en) *	1995-10-31	1998-08-11	Clary Kk	Process for producing all trans-form polyprenols
GB2310138A (en) *	1996-02-19	1997-08-20	Juris Rubens	Immunomodulating plant polyprenols
US5952392A (en) *	1996-09-17	1999-09-14	Avanir Pharmaceuticals	Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US6440980B1 (en) *	1996-09-17	2002-08-27	Avanir Pharmaceuticals	Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
CA2269680A1 (en) *	1996-12-12	1998-06-18	Pharmacia & Upjohn Company	An oil composition of dihydropolyprenols
CA2234326C (en) *	1997-04-25	2001-07-31	Yoshin Tamai	Process for preparing polyprenols
US6784207B2 (en) *	2000-08-04	2004-08-31	Roche Vitamins Inc.	Phytanic acid derivative compositions
JP2005519868A (ja) *	2001-10-16	2005-07-07	アバニール・ファーマシューティカルズ	ｎ−ドコサノールによるウイルス阻害
US7015022B2 (en) *	2002-06-07	2006-03-21	University Of Medicine & Dentistry Of New Jersey	Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities
US20050158329A1 (en)	2004-01-21	2005-07-21	Ghosh Swapan K.	Novel phytol derived immunoadjuvants and their use in vaccine formulations
US11110043B2 (en)	2015-11-16	2021-09-07	Wwu	Alkenone-based formulations for topical applications

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR4055M (de) *	1964-01-20	1966-04-04
GB1459233A (en)	1973-08-29	1976-12-22	Inst Rech Chim Biolog	Medicament containing a higher alkanol
US4059641A (en) *	1975-11-18	1977-11-22	Sankyo Company Limited	Polyprenyl derivatives
JPS5391137A (en) *	1977-01-19	1978-08-10	Sumitomo Chem Co Ltd	Stabilization of agrichemicals
JPS53145922A (en) *	1977-05-26	1978-12-19	Eisai Co Ltd	Remedy for peptic ulcer containing prenyl ketone compound
GB2002231B (en) *	1977-08-10	1982-03-17	Eisai Co Ltd	Hypertension treating agent
US4199587A (en) *	1977-08-10	1980-04-22	Eisai Co., Ltd.	Method of treating hypertension with polyprenyl alcohol ester
JPS6058209B2 (ja) *	1978-12-01	1985-12-19	エーザイ株式会社	β，γ−ジヒドロポリプレニルアルコ−ルおよびそれからなる血圧降下剤
FR2443245A1 (fr) *	1978-12-07	1980-07-04	Nisshin Flour Milling Co	Nouveaux agents anti-ulcere et compositions pharmaceutiques les contenant
EP0041235B1 (de) *	1980-05-30	1985-02-13	Eisai Co., Ltd.	Alpha, beta-dihydropolyprenylderivate zur Behandlung von Leberkrankheiten
CA1165240A (en) *	1980-07-09	1984-04-10	The Procter & Gamble Company	Penetrating topical pharmaceutical compositions
JPS5791932A (en) *	1980-11-28	1982-06-08	Kuraray Co Ltd	Polyprenyl compound
JPS57106618A (en) *	1980-12-24	1982-07-02	Eisai Co Ltd	Anticancer agent consisting of polyprenyl compound
EP0059258B1 (de) *	1980-12-24	1984-05-30	Eisai Co., Ltd.	Polyprenylderivate enthaltende medizinische Zubereitungen, die insbesondere eine Antikrebswirksamkeit besitzen, und therapeutische Zusammensetzungen für die Prevention und Behandlung von Krebs und Hauterkrankungen
GB2122610B (en) *	1982-05-28	1987-04-01	Eisai Co Ltd	A polyprenyl compound and a pharmaceutical composition containing a polyprenyl compound
EP0561305B1 (de) *	1992-03-17	1999-08-11	Eisai Co., Ltd.	Hautbleichendes Mittel enthaltend Teprenone

1983
- 1983-05-25 GB GB08314419A patent/GB2122610B/en not_active Expired
- 1983-05-25 DE DE3318989A patent/DE3318989C2/de not_active Expired - Fee Related
- 1983-05-25 DE DE3348500A patent/DE3348500C2/de not_active Expired - Fee Related
- 1983-05-27 CH CH2902/83A patent/CH654823A5/fr not_active IP Right Cessation
- 1983-05-27 ES ES522789A patent/ES8406992A1/es not_active Expired
- 1983-05-27 DK DK239483A patent/DK171640B1/da not_active IP Right Cessation
- 1983-05-27 NL NL8301892A patent/NL194300C/nl not_active IP Right Cessation
- 1983-05-27 SE SE8303013A patent/SE461650B/sv unknown
- 1983-05-27 CA CA000429108A patent/CA1310660C/en not_active Expired - Fee Related
- 1983-05-30 FR FR838308941A patent/FR2527597B1/fr not_active Expired
- 1983-05-30 AT AT0197283A patent/AT389871B/de not_active IP Right Cessation
- 1983-05-30 IT IT21364/83A patent/IT1164256B/it active
- 1983-10-27 FR FR8317171A patent/FR2532844B1/fr not_active Expired
- 1983-10-27 FR FR8317169A patent/FR2532843A1/fr active Pending
- 1983-10-27 FR FR8317170A patent/FR2532848B1/fr not_active Expired
1984
- 1984-02-15 ES ES529754A patent/ES529754A0/es active Granted
- 1984-02-15 ES ES529753A patent/ES529753A0/es active Granted
1985
- 1985-03-29 GB GB08508216A patent/GB2159055B/en not_active Expired
- 1985-03-29 GB GB08508220A patent/GB2159713A/en not_active Withdrawn
- 1985-03-29 GB GB08508217A patent/GB2159710B/en not_active Expired
- 1985-03-29 GB GB08508214A patent/GB2159054B/en not_active Expired
- 1985-03-29 GB GB08508218A patent/GB2159711B/en not_active Expired
- 1985-03-29 GB GB08508219A patent/GB2159712B/en not_active Expired
- 1985-07-29 US US06/760,221 patent/US4624966A/en not_active Expired - Lifetime
- 1985-09-02 FR FR858513026A patent/FR2569108B1/fr not_active Expired - Lifetime
1988
- 1988-04-22 SE SE8801515A patent/SE502924C2/sv unknown
- 1988-04-22 SE SE8801514A patent/SE502923C2/sv unknown
- 1988-04-22 SE SE8801513A patent/SE502922C2/sv unknown
1996
- 1996-01-11 US US08/584,145 patent/US6111131A/en not_active Expired - Fee Related
- 1996-02-14 US US08/601,489 patent/US6288128B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GB8508217D0 (en)	1985-05-09
FR2532848B1 (fr)	1986-04-11
IT8321364A1 (it)	1984-11-30
US6111131A (en)	2000-08-29
IT8321364A0 (it)	1983-05-30
GB2159710A (en)	1985-12-11
SE8801515D0 (sv)	1988-04-22
GB8508220D0 (en)	1985-05-09
DE3318989C2 (de)	1996-11-21
GB8508219D0 (en)	1985-05-09
FR2532848A1 (fr)	1984-03-16
FR2527597B1 (fr)	1989-02-10
FR2532844A1 (fr)	1984-03-16
SE502924C2 (sv)	1996-02-19
DE3348500C2 (de)	1998-10-22
GB8314419D0 (en)	1983-06-29
CA1310660C (en)	1992-11-24
DK239483D0 (da)	1983-05-27
GB2122610B (en)	1987-04-01
ES8507444A1 (es)	1985-09-01
IT1164256B (it)	1987-04-08
SE8801514D0 (sv)	1988-04-22
GB2159055A (en)	1985-11-27
FR2532843A1 (fr)	1984-03-16
SE502923C2 (sv)	1996-02-19
SE502922C2 (sv)	1996-02-19
CH654823A5 (fr)	1986-03-14
GB2159712A (en)	1985-12-11
ES8506567A1 (es)	1985-07-16
GB2159712B (en)	1987-04-01
FR2532844B1 (fr)	1986-10-03
GB2122610A (en)	1984-01-18
FR2569108B1 (fr)	1990-03-02
US4624966A (en)	1986-11-25
SE8303013D0 (sv)	1983-05-27
SE8303013L (sv)	1983-11-29
FR2527597A1 (fr)	1983-12-02
ES522789A0 (es)	1984-09-01
NL8301892A (nl)	1983-12-16
DE3318989A1 (de)	1983-12-01
FR2569108A1 (fr)	1986-02-21
SE461650B (sv)	1990-03-12
SE8801515L (sv)	1988-04-22
GB2159054B (en)	1987-04-08
GB2159054A (en)	1985-11-27
GB8508214D0 (en)	1985-05-09
GB2159055B (en)	1987-04-08
SE8801514L (sv)	1988-04-22
ES529753A0 (es)	1985-07-16
GB2159711A (en)	1985-12-11
GB2159710B (en)	1987-04-08
AT389871B (de)	1990-02-12
DK171640B1 (da)	1997-03-03
ES8406992A1 (es)	1984-09-01
GB2159713A (en)	1985-12-11
ES529754A0 (es)	1985-09-01
ATA197283A (de)	1989-07-15
SE8801513D0 (sv)	1988-04-22
SE8801513L (sv)	1988-04-22
GB8508218D0 (en)	1985-05-09
NL194300B (nl)	2001-08-01
US6288128B1 (en)	2001-09-11
GB2159711B (en)	1987-04-01
DK239483A (da)	1983-11-29

Publication	Publication Date	Title
NL194300C (nl)	2001-12-04	Farmaceutisch preparaat, dat een polyprenol als werkzaam bestanddeel bevat, alsmede voor toepassing daarin geschikte polyprenolen.
DE3884517T2 (de)	1994-02-10	Biologisch aktive Carbonsäureester.
EP0002228B1 (de)	1984-02-29	Hydroxynaphtochinonderivate, ihre Präparate zur Behandlung und Verhütung von Theileriose bei Vieh und Schafen; Verfahren zu deren Herstellung; Naphtochinonderivate
US4917829A (en)	1990-04-17	3,7,11,15-Tetramethyl-2,4,6,10,14,-hexadecapentaendic acid
EP0077550B1 (de)	1985-07-10	1,4-Naphthochinone, Verfahren zu deren Herstellung, und deren veterinäre Formulierungen
US5280048A (en)	1994-01-18	β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound
KR100224330B1 (ko)	1999-10-15	골관절 질환의 치료에 유용한 n-((4,5-디히드록시-및 4,5,8-트리히드록시-9,10-디히드로-9,10-디옥소-2-안트라센-일)카르보닐)아미노산
US3586701A (en)	1971-06-22	Norzearalane and its production
US3852307A (en)	1974-12-03	Synthesis of zearalanone and related compounds
US5658958A (en)	1997-08-19	β, γ-dihydropolyprenyl alcohol derivatives effective at mitigating stress in animals
EP0067008B1 (de)	1985-08-21	Carbonsaüre ester
NL9900009A (nl)	2001-09-03	Beta, gamma-dihydropolyprenylalcoholderivaten en farmaceutisch preparaat, dat een polyprenylverbinding bevat.
EP0130644B1 (de)	1988-11-02	Verwendung von 2-Pentanoylaminoessigsäure und ihren Salzen
JPS5973533A (ja)	1984-04-25	β，γ−ジヒドロポリプレニルアルコ−ル誘導体
DE725971C (de)	1942-10-03	Verfahren zur Herstellung von Trimethylhydrochinonaethern
EP0210886B1 (de)	1988-08-24	Tertiäre halogenierte Biphenylalkohole die nützlich in der Therapeutik bei der Behandlung von Atheriosklerose sind
GB2159709A (en)	1985-12-11	Pharmaceutical compositions of polyprenyl ketones
JPH0228108A (ja)	1990-01-30	免疫機能不全による疾患の予防・治療剤
DE3348492C2 (de)	1999-11-11	Verwendung eines ß,gamma-Dihydropolyprenylalkoholderivats zur Prophylaxe und Therapie von durch Immunmangelerscheinungen verursachten Infektionskrankheiten
JPS5899462A (ja)	1983-06-13	７−ヒドロキシプロスタグランデイン類
BE896865A (fr)	1983-11-28	Derives de l'alcool beta, alpha-dihydropolyprenylique et composition pharmaceutique contenant un compose de polyprenyle.
FR2532846A1 (fr)	1984-03-16	Composition pharmaceutique comprenant a titre de principe actif le 3,7,11,15 - tetramethyl -1,6,10,14-hexadecatetraene-3-ol
FR2368481A1 (fr)	1978-05-19	Nouveaux butanolides
JPS6222779A (ja)	1987-01-30	新規ジチオラン誘導体およびこれを有効成分とする免疫調節剤

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1990-03-01	BA	A request for search or an international-type search has been filed
1990-04-02	BB	A search report has been drawn up
1990-06-01	BC	A request for examination has been filed
2003-08-01	V4	Discontinued because of reaching the maximum lifetime of a patent	Effective date: 20030527